Immunoprecise Antibodies Ltd Receivables Turnover Ratio (IPA), from the fourth quarter 2024 to the fourth quarter 2023 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Immunoprecise Antibodies Ltd   (NASDAQ: IPA)
 

Immunoprecise Antibodies Ltd Accounts Receivables Turnover Ratio from the fourth quarter 2024 to the fourth quarter 2023

Quarterly Results, Trends, Rankings, Statistics


According to Immunoprecise Antibodies Ltd Balance Sheet, in the fourth quarter 2024, company has not reported any Accounts receivable.
See Immunoprecise Antibodies Ltd Balance Sheet

If we take a look into Healthcare sector 100 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 1025, from overall ranking in the third quarter 2024 at 2258.

What is Receivable Turnover Ratio?
What is Immunoprecise Antibodies Ltd Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IPA Receivables Turnover Ratio (Apr 30 2024)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Apr 30 2023)
IV. Quarter
Y / Y Receivable Change - - - - -
Y / Y Revenue Change 18.65 % - - - -
Receivable Turnover Ratio (TTM) - - - - -
IPA's Total Ranking # 1025 # 2258 # 0 # 0 # 0
Accounts Receivable average collection period days - - - - -
Seq. Receivable Change - - - - -
Seq. Revenue Change - - - - -


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 41
Healthcare Sector # 101
Overall Market # 1025

Receivable Turnover Ratio Statistics
High Average Low
11.46 10.75 10.03
(Apr 30 2024)   (Apr 30 2023)





IPA Company Profile • Back to IPA Efficiency Comparisons • Compare IPA Receivables Turnover Ratio to its Competitors

Financial Statements
Immunoprecise Antibodies Ltd 's Accounts Receivable $ 0 Millions Visit IPA's Balance sheet
Immunoprecise Antibodies Ltd 's Sales TTM $ 19 Millions Visit IPA's Income Statement
Sources of IPA's Revenues Visit IPA's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
IPA's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
IPA's Growth Rates IPA's Roa IPA's Inventory Turnover Ratio IPA's Dividend Comparisons
IPA's Profitability Ratios IPA's Roi IPA's Asset Turnover Ratio IPA's Dividend Growth
IPA's Valuation Ratios IPA's Roe IPA's Financial Strength Ratios IPA's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Apr 30 2024, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Apr 30 2024 Receivable at quarter ending Apr 30 2024

Date modified: 2026-07-24T14:57:57+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.